Research article: Drug-induced glucose-6-phosphate dehydrogenase deficiency-related hemolysis risk assessment

Authors:
Yang Yang;Zuofeng Li;Peng Nan;Xiaoyan Zhang
Affiliations:
School of Life Science and Technology, Tongji University, 1239 SiPing Road, Shanghai 200092, PR China;Shanghai Center for Bioinformation Technology, Shanghai 200235, PR China;Ministry of Education Key Laboratory for Biodiversity Science and Ecological Engineering, School of Life Sciences, Fudan University, Shanghai 200433, PR China;School of Life Science and Technology, Tongji University, 1239 SiPing Road, Shanghai 200092, PR China
Venue:
Computational Biology and Chemistry
Year:
2011

Citing 2
Cited 0

Not So Naive Bayes: Aggregating One-Dependence Estimators

Machine Learning
Efficient lazy elimination for averaged one-dependence estimators

ICML '06 Proceedings of the 23rd international conference on Machine learning

Quantified Score

Hi-index	0.00

Visualization

Abstract

Glucose-6-phosphate dehydrogenase (G6PD) is an essential enzyme that protects human red blood cells from premature destruction caused by oxidative damage. People suffering from G6PD deficiency would be vulnerable to various oxidative substances, such as fava beans and oxidant drugs. Until now, many institutes, organizations or domain experts have compiled low-risk or high-risk drugs collection for patients with G6PD deficiency, mainly from the case report or clinical trails. Recently, we have explored a classification system to predict drug-induced hemolytic potential. In this paper, we screen the normally used over-the-counter (OTC) drugs for ''high-risk'' and ''low-risk'' ones to G6PD deficient patients by this system.